Safety, tolerability and pharmacokinetics of AZD1613 in adults with autosomal dominant polycystic kidney disease

Trial Identifier: D9050C00002
Sponsor: AstraZeneca
Start Date: December 2025
Primary Completion Date: January 2027
Study Completion Date: January 2027

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Hangzhou, CN, 310003
CN Shanghai, CN, 200025
CN Wuhan, CN, 430022
CN Xiamen, CN, 361101
GB London, GB, NW3 2QG
US, CA Loma Linda, CA, US, 92354
US, FL Jacksonville, FL, US, 32216
US, FL Orlando, FL, US, 32808
US, KS Lenexa, KS, US, 66219
US, MN Rochester, MN, US, 55905
US, TX San Antonio, TX, US, 78212